Bristol-Myers' cheap valuation with dividend
The bull case for Bristol-Myers Squibb: its status as a 'have-not' in the drug industry has created a cheap valuation with a high, sustainable dividend and an underappreciated pipeline.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.